NO304829B1 - 3-substituerte oksindolderivater som kaliumkanalmodulatorer - Google Patents

3-substituerte oksindolderivater som kaliumkanalmodulatorer

Info

Publication number
NO304829B1
NO304829B1 NO962232A NO962232A NO304829B1 NO 304829 B1 NO304829 B1 NO 304829B1 NO 962232 A NO962232 A NO 962232A NO 962232 A NO962232 A NO 962232A NO 304829 B1 NO304829 B1 NO 304829B1
Authority
NO
Norway
Prior art keywords
potassium channel
channel modulators
oxindole derivatives
substituted oxindole
substituted
Prior art date
Application number
NO962232A
Other languages
English (en)
Norwegian (no)
Other versions
NO962232L (no
NO962232D0 (no
Inventor
Piyasena Hewawasam
Valentin K Gribkoff
Nicholas A Meanwell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO962232D0 publication Critical patent/NO962232D0/no
Publication of NO962232L publication Critical patent/NO962232L/no
Publication of NO304829B1 publication Critical patent/NO304829B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/38Oxygen atoms in positions 2 and 3, e.g. isatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/60Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
NO962232A 1995-06-07 1996-05-31 3-substituerte oksindolderivater som kaliumkanalmodulatorer NO304829B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/477,047 US5565483A (en) 1995-06-07 1995-06-07 3-substituted oxindole derivatives as potassium channel modulators

Publications (3)

Publication Number Publication Date
NO962232D0 NO962232D0 (no) 1996-05-31
NO962232L NO962232L (no) 1996-12-09
NO304829B1 true NO304829B1 (no) 1999-02-22

Family

ID=23894292

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962232A NO304829B1 (no) 1995-06-07 1996-05-31 3-substituerte oksindolderivater som kaliumkanalmodulatorer

Country Status (25)

Country Link
US (2) US5565483A (cs)
EP (1) EP0747354B1 (cs)
JP (1) JP4011135B2 (cs)
KR (1) KR100432157B1 (cs)
CN (1) CN1076348C (cs)
AR (1) AR004493A1 (cs)
AT (1) ATE195515T1 (cs)
AU (1) AU707760B2 (cs)
BR (1) BR1100180A (cs)
CA (1) CA2176183C (cs)
CZ (1) CZ289248B6 (cs)
DE (1) DE69609772T2 (cs)
DK (1) DK0747354T3 (cs)
ES (1) ES2148685T3 (cs)
GR (1) GR3034523T3 (cs)
HU (1) HU222046B1 (cs)
IL (1) IL118349A (cs)
NO (1) NO304829B1 (cs)
NZ (1) NZ286748A (cs)
PL (1) PL184660B1 (cs)
PT (1) PT747354E (cs)
RU (1) RU2165925C2 (cs)
SG (1) SG70572A1 (cs)
TW (1) TW384284B (cs)
ZA (1) ZA964327B (cs)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504504B (en) * 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
US5808095A (en) * 1997-05-30 1998-09-15 Bristol-Myers Squibb Company Preparation of 3-fluoro oxindole derivatives
US5893085A (en) * 1997-06-10 1999-04-06 Phillips; Ronald W. Dynamic fuzzy logic process for identifying objects in three-dimensional data
US5972894A (en) * 1997-08-07 1999-10-26 Cytran, Inc. Peptides having potassium channel opener activity
CA2301549A1 (en) * 1997-08-28 1999-03-04 Piyasena Hewawasam 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
CA2339406A1 (en) * 1998-08-14 2000-02-24 Elan Pharmaceuticals, Inc. Novel esk potassium channel polypeptide and polynucleotide compositions
EP1133474B1 (en) * 1998-12-04 2007-02-21 Bristol-Myers Squibb Company 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
EP1135123B1 (en) * 1998-12-04 2004-12-29 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
MXPA02001207A (es) * 1999-08-03 2002-07-30 Abbott Lab Abridores de canal de potasio.
AU2001252958A1 (en) 2000-03-23 2001-10-03 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
DK1303269T3 (da) * 2000-06-29 2006-03-20 Neurosearch As 3-substituerede oxindolderivater og deres anvendelse som KCNQ-kaliumkanalmodulatorer
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
WO2002002518A2 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
US20020045566A1 (en) * 2000-10-13 2002-04-18 Gribkoff Valentin K. Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
WO2002066426A2 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
JP2005507853A (ja) 2001-02-20 2005-03-24 ブリストル−マイヤーズ スクイブ カンパニー Kcnqカリウムチャンネルモジュレーター並びに片頭痛および機構的に関連する疾患の治療におけるそれらの使用
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
WO2003002122A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
CA2479256A1 (en) * 2002-03-20 2003-10-02 Bristol-Myers Squibb Company Phosphate prodrugs of fluorooxindoles
US7244756B2 (en) 2002-06-26 2007-07-17 Poseidon Pharmaceuticals A/S Benzimidazol-2-one derivatives and their use
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
CA2503075A1 (en) * 2002-10-21 2004-04-29 Ramot At Tel-Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
KR100456679B1 (ko) * 2002-11-14 2004-11-10 현대모비스 주식회사 차량의 조수석 에어백의 장착구조
US6916937B2 (en) * 2003-02-03 2005-07-12 Bristol-Myers Squibb Company Carbohydrate prodrugs of fluorooxindoles
TW200508197A (en) * 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US7524664B2 (en) 2003-06-17 2009-04-28 California Institute Of Technology Regio- and enantioselective alkane hydroxylation with modified cytochrome P450
AU2004259703A1 (en) * 2003-07-15 2005-02-03 Smithkline Beecham Corporation Novel compounds
WO2005035498A1 (ja) * 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. 含窒素二環性化合物の摂食調節剤としての用途
ES2347152T3 (es) * 2003-11-26 2010-10-26 Pfizer Products Inc. Derivados de aminopirazol como inhibidores de gsk-3.
US7169803B2 (en) * 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
HU0500126D0 (en) * 2005-01-26 2005-04-28 Sanofi Aventis New compounds and process for their preparation
HU0500157D0 (en) * 2005-02-01 2005-04-28 Sanofi Aventis New compounds
HUP0500167A2 (en) * 2005-02-02 2007-03-28 Sanofi Aventis Optically active 4-chloro-3-(5-chloro-3-alkyl-2-oxo-2,3-dihydro-1h-indol-3-yl)benzoic acid derivatives and process for producing them
CA2604759A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AR056980A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
CN101203217A (zh) * 2005-04-24 2008-06-18 惠氏公司 调节膀胱功能的方法
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
BRPI0613430A2 (pt) * 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
CN101410118A (zh) * 2006-03-24 2009-04-15 惠氏公司 疼痛的治疗
RU2008135115A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Способы лечения когнитивных и других расстройств
US8252559B2 (en) * 2006-08-04 2012-08-28 The California Institute Of Technology Methods and systems for selective fluorination of organic molecules
EP2069513A4 (en) * 2006-08-04 2012-03-21 California Inst Of Techn METHOD AND SYSTEMS FOR THE SELECTIVE FLUORINATION OF ORGANIC MOLECULES
US8802401B2 (en) * 2007-06-18 2014-08-12 The California Institute Of Technology Methods and compositions for preparation of selectively protected carbohydrates
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
EP2205079A4 (en) * 2007-10-04 2010-10-27 Merck Sharp & Dohme N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
KR100985286B1 (ko) * 2007-12-28 2010-10-04 주식회사 포스코 내지연파괴 특성이 우수한 고강도 고망간강 및 제조방법
EP2540295A1 (en) * 2011-06-27 2013-01-02 Centre national de la recherche scientifique Compositions for the treatment of Fragile X syndrome
EA033281B1 (ru) 2015-04-29 2019-09-30 Янссен Фармацевтика Нв Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
KR20170141769A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도
AU2018225758A1 (en) 2017-02-24 2019-09-05 Ovid Therapeutics Inc. Methods of treating seizure disorders
US11427531B2 (en) 2017-10-09 2022-08-30 Ramot At Tel-Aviv University Ltd. Modulators of potassium ion and TRPV1 channels and uses thereof
KR102612324B1 (ko) * 2019-01-25 2023-12-12 제이에프이 스틸 가부시키가이샤 고망간 강 주편의 제조 방법 및 고망간 강 강편 또는 강판의 제조 방법
CN110240558B (zh) * 2019-07-10 2022-05-27 上海华理生物医药股份有限公司 一种Flindokalner消旋体的新合成方法
KR102209406B1 (ko) * 2019-11-21 2021-01-29 주식회사 포스코 미세한 주조조직을 갖는 고망간강 및 그 제조방법과 이를 이용한 고망간 강판
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3114351A1 (de) * 1981-04-09 1982-11-04 Hoechst Ag, 6000 Frankfurt "oxindol-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel mit neuroanaboler wirkung"
DE3529994A1 (de) * 1985-08-22 1987-02-26 Hoechst Ag Indolinonderivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
DE3803775A1 (de) * 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US5200422A (en) * 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
NZ239540A (en) * 1990-09-24 1993-11-25 Neurosearch As 1-phenyl benzimidazole derivatives and medicaments
SK278514B6 (en) * 1990-09-25 1997-08-06 Andreas Kiener Rhodococcus erythropolis microorganism and a method for producing hydroxylated pyrazines and quinoxalines
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
JP4011135B2 (ja) 2007-11-21
DE69609772D1 (de) 2000-09-21
US5602169A (en) 1997-02-11
US5565483A (en) 1996-10-15
TW384284B (en) 2000-03-11
AR004493A1 (es) 1998-12-16
CN1144800A (zh) 1997-03-12
KR970001324A (ko) 1997-01-24
CA2176183C (en) 2010-03-30
HU222046B1 (hu) 2003-04-28
RU2165925C2 (ru) 2001-04-27
PT747354E (pt) 2000-11-30
HK1003301A1 (en) 1998-10-23
NO962232L (no) 1996-12-09
GR3034523T3 (en) 2000-12-29
ATE195515T1 (de) 2000-09-15
BR1100180A (pt) 2000-03-14
KR100432157B1 (ko) 2004-10-06
EP0747354A1 (en) 1996-12-11
IL118349A (en) 2000-07-26
NO962232D0 (no) 1996-05-31
ZA964327B (en) 1997-11-28
CA2176183A1 (en) 1996-12-08
DK0747354T3 (da) 2000-09-18
EP0747354B1 (en) 2000-08-16
ES2148685T3 (es) 2000-10-16
AU707760B2 (en) 1999-07-22
AU5475796A (en) 1996-12-19
DE69609772T2 (de) 2001-04-12
PL184660B1 (pl) 2002-11-29
CZ161896A3 (en) 1997-03-12
PL314672A1 (en) 1996-12-09
JPH08333336A (ja) 1996-12-17
SG70572A1 (en) 2000-02-22
NZ286748A (en) 1998-08-26
CZ289248B6 (cs) 2001-12-12
CN1076348C (zh) 2001-12-19
HUP9601547A1 (en) 1997-09-29
IL118349A0 (en) 1996-09-12
HU9601547D0 (en) 1996-08-28

Similar Documents

Publication Publication Date Title
DK0747354T3 (da) 3-substituerede oxindolderivater som kaliumkanalmodulatorer
DK1133474T3 (da) 3-Substituerede 4-arylquinolin-2-onderivater som kaliumkanal-modulatorer
AU2647597A (en) Oxindole derivatives
NO974043D0 (no) Indolderivater som EAA-antagonister
FI962969A0 (fi) Indolijohdannaisia 5-HT1:n agonisteina
EP1011677A4 (en) 4-ARYL-3-AMINOQUINOLEIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS
NO975880L (no) Formylderivater anvendt som ikke-ioniske kontrastmidler
DK0747346T3 (da) N-acyl-2-arylcyclopropylmethylaminderivater som melatonerge midler
KR970702865A (ko) 신규 카르바페넴 유도체(Novel Carbapenem Derivatives)
DE69736371D1 (de) Bieten um Bandbreite
AU6370196A (en) Indole derivatives
ATE193701T1 (de) Substituierte indol-derivate
FI971492L (fi) Indolijohdannaiset 5-HT1-tyyppisinä agonisteina
NO975811D0 (no) Ny anvendelse for pyrrolderivater
ATE210117T1 (de) Indolderivate als melatoninanaloge
AU6370296A (en) Indole derivatives
AU6370096A (en) Indole derivatives
DE59605373D1 (de) Substituierte Indol-Derivate

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees